BTYNB

Research use only, not for human use.

BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA with IC50 of 5 uM.

BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA with IC50 of 5 uM; has no effect on binding of PR to flPRE; destabilizes c-Myc mRNA, downregulates β-TrCP1 mRNA and reduces activation of NF-κB; also decreases oncogenic translation regulator eEF2 mRNA levels in cancer cells; potently inhibits proliferation of IMP1-containing ovarian cancer and melanoma cells with no effect in IMP1-negative cells.(In Vitro):The oncofetal mRNA-binding protein, IMP1 binds to and stabilizes c-Myc, β-TrCP1, and other oncogenic mRNAs, it leads to increased expression of the proteins encoded by its target mRNAs.BTYNB (10 uM; 0.5-1 hour) enhances the degradation rate of c-Myc mRNA in SK-MEL2 cells.BTYNB (10-40 uM; 72 hours) degrades c-Myc expression in a dose-dependent manner in SK-MEL2 cells.BTYNB (10-40 uM; 72 hours) decreases IMP1 expression in a dose-dependent manner in SK-MEL2 cells.BTYNB (1-40 μM; 72 hours) decreases levels of CDC34, CALM1, β-TRCP1, and Col5A1 mRNAs expression in T47D/(A1-2) cells in the presence of hormone.BTYNB elicits a robust dose-dependent inhibition of cell proliferation in IMP1-positive cells with IC50 of 2.3 μM, 3.6 μM, and 4.5 μM in ES-2, IGROV-1, and SK-MEL2 cells, respectively. BTYNB has no effects on IMP1-negative cells and demonstrates no inhibition of cell proliferation at all concentrations tested, including 50 μM.

RT-PCR Cell Line:T47D/(A1-2) cells Concentration:1 μM; 10 μM; 20 μM; 30 μM; 40 μM Incubation Time:Result: Reduced the levels of a diverse set of cancer-related IMP1 mRNA targets.

——

BTYNB IMP1 Inhibitor | MDK6620

Cell Cycle/DNA Damage

c-Myc

c-Myc

——

——

304456-62-0

309.181

C12H9BrN2OS

>98% (HPLC)

In Vitro:?DMSO : 62.5 mg/mL (202.15 mM)

O=C(N)C1=CC=CC=C1/N=C/C2=CC=C(Br)S2

(E)-2-(((5-bromothiophen-2-yl)methylene)amino)benzamide

(-20℃)

With Ice Pack

≥ 2 years